George Goldsmith

George Goldsmith is an American entrepreneur and health-industry consultant based in London whose work with his wife, physician Ekaterina Malievskaia, helped turn psychedelic therapy’s return to public legitimacy into an institutional and commercial project. Through Compass Pathways, he pursued approval for psilocybin-assisted therapy in Europe, backing clinical trials and envisioning treatment centers designed around guided sessions. His role placed him at the meeting point of psychiatric authority, health-care infrastructure, and a continuing debate over whether psychedelics should be chiefly medical treatments or have wider uses.

Identity and Public Role

Goldsmith entered the psychedelic research story not as a clinician but as an organizer and health-industry consultant. At a gathering that brought scientists, underground guides, therapists, funders, filmmakers, and prospective entrepreneurs together, he organized and moderated a plenary panel on the future of psychedelic psychiatry. Its other speakers were Paul Summergrad, former head of the American Psychiatric Association, and Tom Insel, former head of the National Institute of Mental Health. The lineup itself signaled how far psychedelic therapy had moved toward recognition by the mental-health establishment.

Insel described psychedelic-assisted psychotherapy as a novel approach, while warning that its combination of drug and therapy could challenge regulators accustomed to assessing drugs in isolation. When Goldsmith asked what advice the researchers should take away, Insel’s answer was blunt: “Don’t screw it up!” He and Summergrad emphasized safety, rigor, and reputational risk, cautioning that careless research or a disastrous patient experience could damage the field. Goldsmith’s role in convening the panel gave him a place within this effort to make psychedelic treatment institutionally credible, even as the exchange made clear that recognition would depend on how carefully it was developed.

Compass Pathways and the European Trials

In recent years, Goldsmith and Malievskaia devoted substantial energy and resources to winning approval for psilocybin-assisted therapy in the European Union. Goldsmith formed Compass Pathways to develop psychedelic treatment centers and to support a program of clinical trials. He raised three million pounds to fund and organize multi-site European trials, beginning with treatment-resistant depression. Paul Summergrad and Tom Insel joined the company’s advisory board, linking its plans to figures with experience leading major mental-health institutions.

The intended route to wider availability depended on demonstrating that treatment could be both effective and economical enough for Europe’s national health services to reimburse it. This made the trials more than tests of a drug’s potential: they were part of an effort to build a system in which a guided psychedelic session could be offered within established health care. The approach answered a practical obstacle in the field. Psychedelic studies are difficult to blind, and their outcomes may depend not only on the substance but also on the setting, the therapists, and participants’ expectations. A model that explicitly combines pharmacology and psychotherapy takes that context as part of the treatment, rather than treating it as incidental.

Designing a Treatment Setting

Goldsmith imagined a network of psychedelic treatment centers in attractive natural settings, where patients could attend guided sessions. The proposal gave physical form to a therapeutic model that differs from medication taken repeatedly in ordinary clinical settings: the experience would be organized around a supported session, within a purpose-designed environment. Goldsmith was already working with designers at IDEO to rethink the experience of psychedelic therapy as a whole, indicating that the project concerned not only trial results but also how care would be arranged and encountered.

This vision also addressed a financial and institutional mismatch. Phase 3 trials across multiple sites and hundreds of volunteers can cost tens of millions of dollars, while pharmaceutical companies had shown limited interest in psychedelics. Psilocybin is a natural product, and the patent on LSD had expired; moreover, a treatment potentially needed only once does not fit the familiar business model of drugs taken daily for chronic conditions. Goldsmith’s plan joined trial funding, center design, and the prospect of public reimbursement in an attempt to make a different model workable.

Medical Acceptance and Its Limits

Goldsmith’s project stood within a larger argument about what renewed acceptance should mean. For some researchers and therapists, medical acceptance was a first step toward broader cultural acceptance; Goldsmith’s work, as described in the account, concentrated on building a route through trials and health-care institutions. That route promised legitimacy and access, but it also raised the question of whether medicalization might become the only authorized framework. Bob Jesse worried that treating medicalization as the single proper path would be a mistake, while others imagined controlled settings for people seeking psychedelic experiences for spiritual reasons or curiosity as well as for mental health.

Goldsmith’s proposed centers therefore represented both an answer and a boundary: an effort to make psychedelic therapy legible to regulators and health services by organizing it as a guided, structured treatment. His ambition was not simply to establish that psilocybin could help patients, but to connect evidence, therapeutic setting, design, and reimbursement into a possible system of care. The account records these as plans and prospects, not as an accomplished transformation; their significance lies in the institutional pathway he helped put forward.